Lion TCR develops personalized T cell receptor (TCR)-T cell therapy to target Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and chronic HBV infections, utilizing the largest patented TCR library to cover a broad patient population in Asia. Their therapy has demonstrated a three-fold increase in survival time compared to existing treatments, addressing the critical need for effective options against these life-threatening conditions.
Funding
$61.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and chronic HBV infections pose significant challenges, particularly in Asia, where HBV prevalence is high. Existing treatments often fall short, creating a need for more effective and targeted therapeutic options to improve patient survival rates.
Solution
Lion TCR is developing personalized T cell receptor (TCR)-T cell therapy designed to target HBV-related HCC and chronic HBV infections. Their approach leverages a patented TCR library to address a broad patient population, especially those with HLA types common in Asia. The therapy uses transient mRNA expression of TCRs on T-cells to enhance safety and allow for controlled dose escalation in clinical trials. This personalized immunotherapy aims to harness the patient’s own immune system to eliminate the virus and related cancer cells, offering a potentially safer and more effective treatment option.
Target Audience
The primary target audience includes patients with HBV-related hepatocellular carcinoma (HCC) and chronic HBV infections, as well as clinicians specializing in liver cancer treatment and viral infections, particularly in Asia.
Features
- Personalized TCR-T cell therapy targeting HBV-related HCC and chronic HBV infections
- Patented TCR library covering approximately 80% of the patient population, with a focus on prevalent HLA types in Asia
- Transient mRNA expression of TCRs on T-cells for enhanced safety and controlled dose escalation
- GMP-compliant production facility for manufacturing clinical-grade TCR-T cell products
- Ongoing clinical trials evaluating the safety and efficacy of TCR-T cells against HCC